These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11744827)

  • 21. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection.
    Guevara H; Casseb J; Zijenah LS; Mbizvo M; Oceguera LF; Hanson CV; Katzenstein DA; Hendry RM
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):435-40. PubMed ID: 11981358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies.
    Martín JC; Soriano V; Jiménez-Nácher I; Martínez P; González-Lahoz J
    Clin Microbiol Infect; 2001 Dec; 7(12):678-81. PubMed ID: 11843909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of HAART on humoral immune response in primary HIV-1 infected patients.
    Pastori C; Barassi C; Lillo F; Longhi R; Capiluppi B; Nozza S; Galli A; Uberti-Foppa C; Lazzarin A; Tambussi G; Lopalco L
    J Biol Regul Homeost Agents; 2002; 16(1):9-17. PubMed ID: 12003182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.
    Kroon FP; Rimmelzwaan GF; Roos MT; Osterhaus AD; Hamann D; Miedema F; van Dissel JT
    AIDS; 1998 Dec; 12(17):F217-23. PubMed ID: 9863863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure.
    Vallejo A; Ruiz-Mateos E; Molina-Pinelo S; Soriano-Sarabia N; de Felipe B; Gutierrez S; Sánchez-Quijano A; Lissen E; Leal M
    Viral Immunol; 2006; 19(4):759-67. PubMed ID: 17201671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune restoration under HAART in patients chronically infected with HIV-1: diversity of T, B, and NK immune responses.
    Le Guillou-Guillemette H; Renier G; Vielle B; Abgueguen P; Chennebault JM; Lunel F; Payan C
    Viral Immunol; 2006; 19(2):267-76. PubMed ID: 16817769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.